Ledipasvir (formerly GS-5885), Treatment of chronic Hepatitis C infection

New Drug Approvals

File:Ledipasvir.svg

Ledipasvir (formerly GS-5885), Treatment of chronic Hepatitis C infection

Ledipasvir nonproprietary drug name

http://www.ama-assn.org/resources/doc/usan/ledipasvir.pdf

November 28, 2012. N12/139. STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL. USAN ZZ-132. LEDIPASVIR.

MOLECULAR FORMULA C49H54F2N8O6
MOLECULAR WEIGHT 889
Gilead Sciences
CODE DESIGNATION GS-5885
CAS REGISTRY NUMBER 1256388-51-8

Ledipasvir (formerly GS-5885) is an experimental drug for the treatment of hepatitis C being developed by Gilead Sciences.[1] It is currently in Phase III clinical trials.[2] It is being studied in combination with other direct-acting antiviral agents that interfere with HCV replication.

Ledipasvir is an inhibitor of the hepatitis C virus HCV NS5A protein.

Ledipasvir is being tested in interferon-free regimens with other direct-acting antiviral agents for hepatitis C.

Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the HCV protease inhibitor sofosbuvir, ledipasvir…

View original post 121 more words

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s